Evaluation and Monitoring of Patients with Acute Heart Failure Syndromes

• Published in: The American journal of cardiology 2005-09, Vol.96 (6), p.32-40
• Main Authors: Nohria, Anju, Mielniczuk, Lisa M., Warner Stevenson, Lynne
• Format: Article
• Language: English
• Subjects: Acute Disease; Biological and medical sciences; Cardiology. Vascular system; Catheterization, Swan-Ganz; Catheters; Drug therapy; Echocardiography; Heart; Heart failure; Heart Failure - diagnosis; Heart Failure - diagnostic imaging; Heart Failure - physiopathology; Heart failure, cardiogenic pulmonary edema, cardiac enlargement; Humans; Medical sciences; Natriuretic Peptide, Brain; Peptides; Physical Examination; Physical examinations; Pulmonary arteries; Syndrome
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2005.07.019

Advanced heart failure (HF) is associated with frequent hospitalizations, poor quality of life, and increased mortality. Despite optimal medical management, readmission rates remain high and account for approximately two thirds of all costs related to HF management. Evaluation of patients with HF is critical for the appropriate selection and monitoring of therapy as well as for the prevention of recurrent hospitalizations. This evaluation can be complex and relies on integration of the bedside evaluation and information available from invasive and other noninvasive diagnostic techniques. The clinical examination remains the cornerstone of HF evaluation. Key features of the history and physical examination can be used to assign hemodynamic profiles based on the absence or presence of congestion and adequacy of perfusion. These hemodynamic profiles provide prognostic information and may be used to guide therapy. Direct measurement of hemodynamics may be helpful in patients in whom the physical examination is limited or discordant with symptoms. Although the pulmonary artery catheter (PAC) is not recommended during routine therapy of patients hospitalized with HF, it is reasonable to consider the use of PAC monitoring to adjust therapy in patients who demonstrate recurrent or refractory symptoms despite ongoing standard therapy adjusted according to clinical assessment. This is particularly relevant in centers with experience in hemodynamic monitoring for HF. B-type natriuretic peptide (BNP) testing has been shown to facilitate diagnosis of the etiology of dyspnea in the urgent setting for patients without a prior diagnosis of HF. Furthermore, BNP levels provide important prognostic information in patients with chronic HF, but serial BNP testing has not been validated as a guide to inpatient or outpatient management. Echocardiographic assessment can provide prognostic information about ventricular function and size as well as information about hemodynamic status. Development of validated and reproducible noninvasive techniques to monitor patients with acute HF will be an important step in maximizing interventions to improve outcomes in this patient population.